MET and neoplasm: Despite their demonstrated efficacy in OS, c-MET-targeted therapies face significant clinical challenges due to limitations associated with monotherapies, including compensatory activation of alternative signalling pathways, the development of drug resistance, and tumour microenvironmental adaptation.